Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)

NCT02558348 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

12

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor termination

Conditions

Endometrial Cancer
Ovarian Cancer
Cervical Cancer

Interventions

DRUG: AL3818

Sponsor

Advenchen Laboratories, LLC